Helix BioPharma Strengthens Executive Leadership Ahead of U.S. Listing and Next Clinical Phase

Helix BioPharma Corp. (TSX:HBP, OTC PINK:HBPCD, FRANKFURT:HBP0) has appointed Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations, the company announced today. These additions to the executive leadership team come as Helix prepares for a planned U.S. securities exchange listing and advances L-DOS47 into the next stage of clinical development.

L-DOS47, the company's lead candidate, is an antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. The upcoming LDOS007 study is a planned Phase IB/Randomized Phase II trial in first-line non-small cell lung cancer (NSCLC). According to the company, the appointments strengthen the legal, governance, and operational infrastructure needed to support Helix's next phase of growth.

"The next stage of Helix's evolution demands a different kind of company than the one we were building two years ago," said Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix BioPharma. "As we prepare for our planned U.S. securities exchange listing and advance L-DOS47 into its next stage of clinical development, we are deliberately strengthening every part of the organization."

Mehrling highlighted the company's progress on its capital markets roadmap, including the preparation of a base shelf prospectus and the completion of an auditor review of second-quarter financials. "Helen and David are exceptional additions to Helix. Helen brings decades of experience navigating the legal and governance challenges faced by growing life sciences companies, while David has successfully led complex global oncology programs from planning through execution," he added.

Helen Middleton, a qualified life sciences lawyer and registered clinical pharmacist, brings over 30 years of experience from roles at Sidley Austin LLP, Matheson LLP, Mundipharma International, Ipsen, and Abcam. Most recently, she served as Legal Consultant to Kyowa Kirin International. As General Counsel, she will oversee legal affairs, governance, compliance, and strategic transactions.

David Browning brings more than 30 years of experience leading global clinical development programs across biotechnology, pharmaceutical, and academic sectors. He has overseen over 30 Phase I-III clinical studies spanning first-in-human through regulatory approval, with expertise in immunotherapies, targeted therapies, antibody-drug conjugates, and cell therapies. As Vice President of Clinical Operations, he will lead operational planning and execution for Helix's clinical programs, including LDOS007.

Helix BioPharma is an oncology company focused on hard-to-treat cancers. Its pipeline includes L-DOS47, next-generation bi-specific antibody-drug conjugates in discovery, and two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, an oral gemcitabine prodrug. More information is available at https://www.helixbiopharma.com/.